Churchill Capital Corp XI
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael S. Klein
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- 640 Fifth Avenue, 12th Floor New York NY United States of America 10019
- IPO Date
- Feb 9, 2026
- CIK
- 0002074973
- Website
- churchillcapitalcorp.com
- Similar Companies
- Business
- ChemoCentryx, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of orally administered small molecule therapeutics targeting inflammatory disorders, autoimmune diseases, and cancer. The company’s core products include TAVNEOS (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor approved for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis). TAVNEOS is also in late-stage clinical development for severe hidradenitis suppurativa, complement 3 glomerulopathy, and lupus nephritis. In addition to TAVNEOS, ChemoCentryx develops CCX559, an orally administered inhibitor targeting programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1) for cancer therapy, and CCX507, an orally administered inhibitor of chemokine receptor CCR9 for inflammatory bowel disease, which has completed Phase I clinical trials. The company also holds early-stage drug candidates targeting Th17-driven diseases and chemokine receptor CCR6 for other inflammatory and autoimmune conditions. Founded in 1997 and headquartered in San Carlos, California, ChemoCentryx operates as a subsidiary of Amgen Inc. following its acquisition in 2022. Recent major changes include the completion of the acquisition by Amgen in 2022, a transaction valued at approximately $4 billion that integrated ChemoCentryx into Amgen’s rare disease and inflammation franchises. Post-acquisition, ChemoCentryx expanded its development pipeline within Amgen’s infrastructure, accelerating clinical programs for TAVNEOS and other candidates. Regulatory milestones include TAVNEOS’ market approval in the U.S. for ANCA-associated vasculitis and its European Union approval as a treatment combined with rituximab or cyclophosphamide. The company’s strategic focus remains on orphan and rare diseases with high unmet medical needs, leveraging its expertise in chemokine and chemoattractant receptor pathways to innovate disease-modifying therapies that selectively block pathological immune system cascades without broad immunosuppression. ChemoCentryx targets the biopharmaceutical sectors of autoimmune, inflammatory, and oncology diseases, with a geographic focus primarily in the United States and parts of Europe. The company’s product portfolio emphasizes oral therapeutics designed to improve patient adherence and quality of life. With a commitment to advancing treatment paradigms in rare and orphan diseases, ChemoCentryx continues to pursue clinical development and commercialization initiatives across multiple high-impact disease areas under Amgen ownership. The company’s research and development pipeline broadens its reach into immune-oncology and chronic inflammatory diseases, addressing both common and rare conditions through precision targeting of chemoattractant receptors. This comprehensive strategy aligns with ChemoCentryx’s founding mission and recent operational expansion, positioning it as a key player in biopharmaceutical innovation under the Amgen umbrella. The company maintains its focus on advancing orally administered small molecules that provide selective immunomodulation, reflecting its scientific expertise and commitment to patient-centric drug development. The integration with Amgen supports leveraging additional resources and capabilities to accelerate new drug approvals and market access globally.
Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.'s Directors and Officers for Breach of Fiduciary Duties – CCXI
Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth
Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ONEM, CCXI, AERI, SFT
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy
Get ready for more merger mania in pharma sector the rest of the year
Shareholder Alert - The M&A Class Action Firm Announces the Investigation of ChemoCentryx, Inc. - CCXI
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?
ChemoCentrix Spikes 110% on Amgen Acquisition Deal
SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ChemoCentryx, Inc. Buyout
ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why
ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition